Amicus Therapeutics Announces First Quarter 2017 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
Amicus Therapeutics (FOLD) Misses Q1 EPS by 3c
May 9, 2017 7:36 AM EDTAmicus Therapeutics (NASDAQ: FOLD) reported Q1 EPS of ($0.39), $0.03 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $4.16 million.
100+ Fabry Disease Patients Now on Reimbursed Galafold (migalastat) in the EUOn Target to Reach 300... More